Aurobindo Pharma Limited has successfully concluded its postal ballot process with shareholders overwhelmingly approving the appointment of Dr. Punita Kumar Sinha as Independent Director. The voting process, conducted entirely through remote e-voting system, concluded on March 28, 2026, with the resolution passing with requisite majority.

Voting Results and Participation

The postal ballot witnessed strong shareholder participation across all categories. MRR & Associates, Company Secretaries, served as the scrutinizer for the voting process and submitted their report on March 30, 2026.

Category-wise Voting Breakdown

The voting saw unanimous support from the promoter and promoter group, while institutional and non-institutional public shareholders also demonstrated strong approval.

Promoter and Promoter Group

• Shares Held: 300,948,721
• Votes Polled: 300,948,721 (100.00% participation)
• Votes in Favor: 300,948,721 (100.00%)
• Votes Against: 0 (0.00%)

Public Institutions

• Shares Held: 220,994,604
• Votes Polled: 194,281,955 (87.91% participation)
• Votes in Favor: 188,971,509 (97.27%)
• Votes Against: 5,310,446 (2.73%)

Public Non-Institutions

• Shares Held: 58,858,298
• Votes Polled: 18,214,325 (30.95% participation)
• Votes in Favor: 18,201,009 (99.93%)
• Votes Against: 13,316 (0.07%)

Director Appointment Details

The approved resolution pertains to the appointment of Dr. Punita Kumar Sinha (DIN: 05229262) as Independent Director of the company. Key aspects of the appointment include:

Postal Ballot Process Timeline

The postal ballot process was conducted in accordance with regulatory requirements and MCA circulars. The company followed a structured timeline for the voting process:

• Notice Date: February 9, 2026
• Notice Dispatch: February 24, 2026
• Advertisement Publication: February 25, 2026
• Cut-off Date: February 20, 2026
• Voting Commencement: February 27, 2026 (9:00 AM IST)
• Voting Conclusion: March 28, 2026 (5:00 PM IST)
• Scrutinizer Report: March 30, 2026

Regulatory Compliance and Documentation

The postal ballot was conducted in compliance with Section 108 and 110 of the Companies Act, 2013, and various MCA circulars. Kfin Technologies Limited facilitated the e-voting process, while the voting results and scrutinizer's report have been uploaded on the company's website and the e-voting platform. The company has 250,291 shareholders on record as of the cut-off date, with the process conducted entirely through electronic means without physical dispatch of postal ballot forms.

Aurobindo Pharma 's wholly owned subsidiary CuraTeQ Biologics Private Limited has announced a strategic partnership with STADA Arzneimittel AG to expand its biosimilar presence in European markets. The marketing and distribution agreement was disclosed under Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Partnership Details

The collaboration between CuraTeQ Biologics and STADA Arzneimittel AG encompasses the marketing and distribution of two EMA-approved biosimilars in select European Union territories. The agreement covers key markets including France and Germany, positioning CuraTeQ to leverage STADA's established distribution network across these regions.

Strategic Benefits

The partnership is designed to deliver multiple strategic advantages for CuraTeQ Biologics. The agreement is expected to expand the company's market reach significantly while driving revenue growth through access to established European markets. By partnering with STADA, CuraTeQ gains access to an experienced distribution network that has deep market penetration in the targeted EU territories.

New brand names will be created and registered for each biosimilar as part of the marketing strategy, allowing for tailored market positioning in the respective territories. This approach enables both companies to optimize their market presence while maintaining distinct brand identities for the biosimilar products.

Regulatory Compliance

The company has clarified that this agreement does not constitute a material event as per Regulation 30(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The announcement was made in compliance with standard disclosure requirements for listed companies.

CuraTeQ Biologics, focused specifically on biosimilars development and commercialization, continues to strengthen its position in the European pharmaceutical market through strategic partnerships. The collaboration with STADA represents a significant step in the subsidiary's expansion strategy for its EMA-approved biosimilar portfolio.